{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=28",
    "query": {
      "intervention": "Serum Biomarkers",
      "page": 28
    },
    "page_size": 10
  },
  "pagination": {
    "page": 28,
    "page_size": 10,
    "total_count": 821,
    "total_pages": 83,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=29&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Serum+Biomarkers&page=27&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-16T15:15:10.517Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00339703",
      "title": "Levels of Serum Resistin in Asthmatics as a Potential Marker of Systemic Inflammation and Disease State.",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "59th Medical Wing",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2004-11",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00339703"
    },
    {
      "nct_id": "NCT00688246",
      "title": "Bone Mineral Density in Postmenopausal Women at Increased Risk of Breast Cancer And Who Are Receiving Exemestane on MAP3",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Osteoporosis"
      ],
      "interventions": [
        {
          "name": "biologic sample preservation procedure",
          "type": "OTHER"
        },
        {
          "name": "dual x-ray absorptometry",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "NCIC Clinical Trials Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "35 Years and older · Female only"
      },
      "enrollment_count": 238,
      "start_date": "2008-07-10",
      "completion_date": "2013-01-10",
      "has_results": false,
      "last_update_posted_date": "2023-08-04",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 13,
      "location_summary": "Torrance, California • Washington D.C., District of Columbia • Scarborough, Maine + 9 more",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Scarborough",
          "state": "Maine"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00688246"
    },
    {
      "nct_id": "NCT01746810",
      "title": "IR-guided Ablation (IRGA) Combined With Stereotactic Ablative Radiation (SABR) for Large Lung Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Stereotactic body RT and IRGA",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "New Mexico Cancer Research Alliance",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2012-07",
      "completion_date": "2015-10-13",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01746810"
    },
    {
      "nct_id": "NCT03068624",
      "title": "Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Malignant Neoplasm in the Liver",
        "Metastatic Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous CD8+ SLC45A2-specific T Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2017-09-08",
      "completion_date": "2025-07-31",
      "has_results": false,
      "last_update_posted_date": "2024-01-25",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03068624"
    },
    {
      "nct_id": "NCT02771808",
      "title": "Haptoglobin Polymorphism as a Determinant of Adverse Outcome After Cardiac Surgery in Diabetic Patients",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "biomarker samples",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2010-09",
      "completion_date": "2015-05",
      "has_results": false,
      "last_update_posted_date": "2016-05-13",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Charlottesville, Virginia",
      "locations": [
        {
          "city": "Charlottesville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02771808"
    },
    {
      "nct_id": "NCT01873833",
      "title": "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER2-positive Breast Cancer",
        "Recurrent Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of Southern California",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 10,
      "start_date": "2013-07-29",
      "completion_date": "2021-03-02",
      "has_results": true,
      "last_update_posted_date": "2023-10-05",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01873833"
    },
    {
      "nct_id": "NCT01305213",
      "title": "Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fosbretabulin Tromethamine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 107,
      "start_date": "2011-03-21",
      "completion_date": "2016-11-03",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 51,
      "location_summary": "Phoenix, Arizona • Burbank, California • Concord, California + 40 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305213"
    },
    {
      "nct_id": "NCT00734890",
      "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Lymphoma",
        "Lymphoproliferative Disorder",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "vandetanib",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-03",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-03-16",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734890"
    },
    {
      "nct_id": "NCT03015740",
      "title": "Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Clear Cell Renal Cell Carcinoma",
        "Metastatic Kidney Carcinoma",
        "Stage III Renal Cell Cancer AJCC v7",
        "Stage IV Renal Cell Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sitravatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-04-23",
      "completion_date": "2022-09-06",
      "has_results": true,
      "last_update_posted_date": "2024-11-19",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03015740"
    },
    {
      "nct_id": "NCT02158520",
      "title": "Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Mucosal Melanoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Stage IV Uveal Melanoma AJCC v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Academic and Community Cancer Research United",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2013-10-18",
      "completion_date": "2019-10-30",
      "has_results": true,
      "last_update_posted_date": "2020-01-21",
      "last_synced_at": "2026-10-16T15:15:10.517Z",
      "location_count": 13,
      "location_summary": "San Francisco, California • Jacksonville, Florida • Chicago, Illinois + 10 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02158520"
    }
  ]
}